Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125

被引:161
作者
Van Calster, Ben
Timmerman, Dirk
Bourne, Tom
Testa, Antonia Carla
Van Holsbeke, Caroline
Domali, Ekaterini
Jurkovic, Davor
Neven, Patrick
Van Huffel, Sabine
Valentin, Lil
机构
[1] Katholieke Univ Leuven, Univ Hosp, Dept Obstet & Gynaecol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Dept Elect Engn, Louvain, Belgium
[3] Univ London, St Georges Hosp, Sch Med, Dept Obstet & Gynaecol, London, England
[4] Univ Cattolica Sacro Cuore, Inst Clin Ostetrica & Ginecol, Rome, Italy
[5] Kings Coll Hosp London, Dept Obstet & Gynaecol, London, England
[6] Lund Univ, Malmo Gen Hosp, Dept Obstet & Gynaecol, S-21401 Malmo, Sweden
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 22期
关键词
D O I
10.1093/jnci/djm199
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Subjective evaluation of gray-scale and Doppler ultrasound findings (i. e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal ( i. e., ovarian, paraovarian, or tubal) masses. We compared the diagnostic performance of these methods in a large multicenter study. Methods In a prospective multicenter study-the International Ovarian Tumor Analysis-1066 women with a persistent adnexal mass underwent transvaginal gray-scale and color Doppler ultrasound examinations by an experienced examiner within 120 days of surgery. Pattern recognition was used to classify a mass as benign or malignant. Of these women, 809 also had blood collected preoperatively for measurement of serum CA-125. Various levels of CA-125 were used as cutoffs to classify masses. Results from both assays were then compared with histologic findings after surgery. Results Pattern recognition correctly classified 93% (95% confidence interval [CI]=90.9% to 94.6%) of the tumors as benign or malignant. Serum CA-125 correctly classified at best 83% ( 95% CI=80.3% to 85.6%) of the masses. Histologic diagnoses that were most often misclassified by CA-125 were fibroma, endometrioma, and abscess ( false-positive results) and borderline tumor ( false-negative results). Pattern recognition correctly classified 86% ( 95% CI=81.1% to 90.4%) of masses of these four histologic types as being benign or malignant, whereas a serum CA-125 at a cutoff of 30 U/mL correctly classified 41% ( 95% CI=34.4% to 47.5%) of them. Pattern recognition assigned a correct specific histologic diagnosis to 333 (59%, 95% CI=54.5% to 62.8%) of the 567 benign lesions. Conclusion Pattern recognition was superior to serum CA-125 for discrimination between benign and malignant adnexal masses.
引用
收藏
页码:1706 / 1714
页数:9
相关论文
共 48 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values [J].
Bon, GG ;
Kenemans, P ;
Verstraeten, R ;
vanKamp, GJ ;
Hilgers, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) :107-114
[3]  
BONFRER JMG, 1994, EUR J CLIN CHEM CLIN, V32, P201
[4]   TRANS-VAGINAL COLOR FLOW IMAGING - A POSSIBLE NEW SCREENING TECHNIQUE FOR OVARIAN-CANCER [J].
BOURNE, T ;
CAMPBELL, S ;
STEER, C ;
WHITEHEAD, MI ;
COLLINS, WP .
BRITISH MEDICAL JOURNAL, 1989, 299 (6712) :1367-1370
[5]   SERUM CA-125 CONCENTRATIONS IN PATIENTS WITH BENIGN OVARIAN-TUMORS [J].
BUAMAH, PK ;
SKILLEN, AW .
JOURNAL OF SURGICAL ONCOLOGY, 1994, 56 (02) :71-74
[6]   TUMOR-MARKER TRENDS IN ASYMPTOMATIC WOMEN AT RISK FOR OVARIAN-CANCER - RELEVANCE FOR OVARIAN-CANCER SCREENING [J].
CANE, P ;
AZEN, C ;
LOPEZ, E ;
PLATT, LD ;
KARLAN, BY .
GYNECOLOGIC ONCOLOGY, 1995, 57 (02) :240-245
[7]   Preoperative CA 125 levels: An independent prognostic factor for epithelial ovarian cancer [J].
Cooper, BC ;
Sood, AK ;
Davis, CS ;
Ritchie, JM ;
Sorosky, JI ;
Anderson, B ;
Buller, RE .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (01) :59-64
[8]  
Davelaar EM, 1998, CLIN CHEM, V44, P1417
[9]   Sonographic assessment of non-malignant ovarian cysts: does sonohistology exist? [J].
de Kroon, CD ;
van der Sandt, HAGM ;
van Houwelingen, JC ;
Jansen, FW .
HUMAN REPRODUCTION, 2004, 19 (09) :2138-2143
[10]   CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use [J].
Duffy, MJ ;
Bonfrer, JM ;
Kulpa, J ;
Rustin, GJS ;
Soletormos, G ;
Torre, GC ;
Tuxen, MK ;
Zwirner, M .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :679-691